Association of mildly elevated pulmonary vascular resistance with major cardiovascular events in pulmonary hypertension and chronic kidney disease: A retrospective cohort analysis

Pulmonary hypertension caused by fibrosing mediastinitis (PH-FM) is a high-risk condition with limited validated tools for prognostic assessment. Although diffusing capacity of the lung for carbon monoxide (DLCO) predicts outcomes in several cardiopulmonary diseases, its prognostic value in PH-FM remains unclear.

Pulmonary hypertension (PH) and right ventricular (RV) dysfunction increase mortality in multivessel pediatric pulmonary vein stenosis (PVS). Pulmonary vasodilator use is limited in PVS due to the perceived risk of pulmonary edema. We aimed to describe our experience with pulmonary vasodilators in PVS and to assess changes in RV function and hemodynamics over time.

Pulmonary hypertension (PH) is frequently accompanied by a decline in kidney function. In this retrospective cohort, worsening PH was associated with long-term eGFR decline only when accompanied by transition from acute kidney injury (AKI) to acute kidney disease (AKD), defined as persistent kidney dysfunction beyond 7 days after AKI onset, whereas early AKI reversal was not.

In this PH Community Call, we discussed: 

• Subcutaneous Treprostinil in PH Associated With Left Heart Disease or Chronic Lung Disease
• Ferroportin Inhibition Attenuates Pulmonary Hypertension in Hypoxic Sickle Cell Disease Mice 
• Artificial Intelligence-Based Echocardiography in Pulmonary Arterial Hypertension